| 纯度 | >85% SDS-PAGE |
| 种属 | Human |
| 靶点 | CBR3 |
| Uniprot No | O75828 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-277aa |
| 氨基酸序列 | MSSCSRVALV TGANRGIGLA IARELCRQFS GDVVLTARDV ARGQAAVQQL QAEGLSPRFH QLDIDDLQSI RALRDFLRKE YGGLNVLVNN AAVAFKSDDP MPFDIKAEMT LKTNFFATRN MCNELLPIMK PHGRVVNISS LQCLRAFENC SEDLQERFHS ETLTEGDLVD LMKKFVEDTK NEVHEREGWP NSPYGVSKLG VTVLSRILAR RLDEKRKADR ILVNACCPGP VKTDMDGKDS IRTVEEGAET PVYLALLPPD ATEPQGQLVH DKVVQNW |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CBR3重组蛋白的3篇代表性文献示例(内容为假设性概括，仅供参考)：
---
1. **文献名称**: "Expression and Characterization of Recombinant Human Carbonyl Reductase 3"
**作者**: Hoffmann F. et al.
**摘要**: 研究报道了人源CBR3重组蛋白在大肠杆菌中的高效表达与纯化方法，分析了其酶动力学特性，证实其对多种羰基化合物(如异前列腺素)的还原活性，并探讨了其代谢功能。
2. **文献名称**: "Structural Insights into CBR3-Mediated Drug Resistance in Cancer Therapy"
**作者**: Oppermann U. et al.
**摘要**: 通过X射线晶体学解析了CBR3重组蛋白的三维结构，揭示了其底物结合口袋的关键氨基酸残基，解释了该酶如何参与化疗药物(如阿霉素)的代谢及肿瘤耐药性机制。
3. **文献名称**: "Functional Polymorphisms of CBR3 and Their Impact on Anthracycline Cardiotoxicity"
**作者**: Lancker J.V. et al.
**摘要**: 利用重组CBR3蛋白模型，研究其基因多态性对酶活性的影响，发现特定突变(如V244M)显著改变酶对蒽环类药物的代谢效率，为临床药物毒性差异提供分子依据。
---
**注**：以上为模拟文献摘要，实际文献需通过PubMed、Web of Science等数据库检索关键词(如“CBR3 recombinant protein”“Carbonyl Reductase 3 expression”)获取。
CBR3 (Carbonyl Reductase 3) is a member of the short-chain dehydrogenase/reductase (SDR) superfamily, primarily involved in the reduction of carbonyl-containing compounds, such as endogenous metabolites, xenobiotics, and drugs. This NADPH-dependent enzyme plays a critical role in phase I metabolism, converting reactive aldehydes and ketones into less toxic alcohols. CBR3 is notably expressed in tissues like the liver, heart, and kidneys, where it contributes to detoxification pathways and modulates oxidative stress responses. Its activity has been linked to the metabolism of anthracycline chemotherapeutic agents (e.g., doxorubicin), influencing drug efficacy and toxicity, particularly cardiotoxicity. Genetic polymorphisms in CBR3 are associated with interindividual variability in drug responses, underscoring its pharmacogenetic relevance.
Recombinant CBR3 protein is produced via heterologous expression systems (e.g., E. coli, mammalian cells) to study its enzymatic mechanisms, substrate specificity, and interactions. Its recombinant form enables high-purity, scalable production for structural studies (e.g., X-ray crystallography) and functional assays. Researchers utilize it to explore roles in cancer drug resistance, metabolic disorders, and oxidative damage. Additionally, it serves as a tool for screening inhibitors or activators to modulate CBR3 activity in therapeutic contexts. The protein’s structure-function relationships and regulatory pathways remain active areas of investigation, with implications for personalized medicine and toxicology. Overall, CBR3 recombinant protein is a vital resource for deciphering biochemical pathways and developing strategies to optimize drug therapies while mitigating adverse effects.
×
